PROCEPT BioRobotics (NASDAQ:PRCT) Announces Quarterly Earnings Results, Misses Estimates By $0.01 EPS

PROCEPT BioRobotics (NASDAQ:PRCT) released its earnings results on Tuesday. The company reported ($0.47) EPS for the quarter, missing the consensus estimate of ($0.46) by ($0.01), FiscalAI reports. The company had revenue of $94.50 million for the quarter, compared to analyst estimates of $92.77 million. PROCEPT BioRobotics had a negative net margin of 31.82% and a negative return on equity of 27.70%. PROCEPT BioRobotics’s revenue for the quarter was up 19.3% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.35) earnings per share.

Here are the key takeaways from PROCEPT BioRobotics’ conference call:

• Q2 revenue rose 19% year over year to $94.5 million, supported by 65 HYDROS system placements, stronger pricing, and 32% growth in U.S. system revenue. Management maintained its full-year revenue guidance of $390 million to $410 million.
• U.S. procedures increased 21% to more than 13,100 but came in below expectations, primarily because of softness in legacy AquaBeam accounts. Full-year procedure guidance was reduced to 54,000–56,000, with the low end assuming no improvement in AquaBeam utilization.
• HYDROS accounts are generating significantly more procedures per account than legacy AquaBeam sites, while launch-team-supported accounts are showing faster time to first case and stronger early utilization. PROCEPT is accelerating replacements, completing 14 in Q2 and now expecting approximately 40 for the full year.
• Operating expenses increased to $89.8 million, driving a $26.9 million net loss and an $11.3 million adjusted EBITDA loss in Q2. The company raised full-year operating expense guidance to $355 million–$360 million, although it still expects positive adjusted EBITDA in Q4.
• The American Urological Association strengthened its recommendation for Aquablation, and PROCEPT completed enrollment of all 280 patients in the WATER IV randomized prostate cancer trial. The company also received FDA IDE approval for a second randomized trial comparing Aquablation with active surveillance.

PROCEPT BioRobotics Price Performance

NASDAQ:PRCT traded up $1.03 during trading hours on Wednesday, reaching $19.31. The company had a trading volume of 2,588,376 shares, compared to its average volume of 1,593,067. The company has a quick ratio of 5.51, a current ratio of 6.73 and a debt-to-equity ratio of 0.15. The stock has a 50-day moving average of $21.99 and a two-hundred day moving average of $24.97. PROCEPT BioRobotics has a one year low of $16.67 and a one year high of $47.97. The firm has a market capitalization of $1.10 billion, a PE ratio of -10.60 and a beta of 0.89.

More PROCEPT BioRobotics News

Here are the key news stories impacting PROCEPT BioRobotics this week:

• Positive Sentiment: Second-quarter revenue reached $94.5 million, exceeding the $92.77 million consensus estimate and increasing 19.3% year over year. The result provides evidence of continued demand for PROCEPT’s urology-focused surgical robotics platform. PROCEPT BioRobotics Reports Second Quarter 2026 Financial Results
• Neutral Sentiment: PROCEPT projected fiscal-year 2026 revenue of $390 million to $410 million, compared with analysts’ $397.2 million estimate. The range is broadly consistent with expectations, although the company still anticipates a loss; quarterly EPS of negative $0.47 was just below the expected negative $0.46. PROCEPT Reports Q2 Loss, Beats Revenue Estimates
• Negative Sentiment: Wells Fargo downgraded PRCT from “overweight” to “equal weight” and set a $19 price target, signaling limited near-term upside and a more cautious view of the company’s outlook. Wells Fargo Downgrade
• Negative Sentiment: Multiple law firms publicized a securities-fraud class action covering investors who bought shares from February 28, 2024, through February 25, 2026. Allegations include misleading disclosures about product demand, discounted bulk handpiece orders, channel stuffing, and excess customer inventory. Investors may seek lead-plaintiff status by September 22, 2026. The litigation creates legal, reputational, and execution risks for PROCEPT. Kaplan Fox Securities Fraud Lawsuit Notice

Institutional Investors Weigh In On PROCEPT BioRobotics

Large investors have recently made changes to their positions in the company. Virtu Financial LLC bought a new position in PROCEPT BioRobotics during the 4th quarter valued at about $469,000. T. Rowe Price Investment Management Inc. grew its stake in PROCEPT BioRobotics by 59.4% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 3,271,408 shares of the company’s stock worth $102,919,000 after buying an additional 1,218,815 shares during the last quarter. Invesco Ltd. increased its holdings in shares of PROCEPT BioRobotics by 19.8% during the fourth quarter. Invesco Ltd. now owns 43,570 shares of the company’s stock worth $1,371,000 after buying an additional 7,191 shares in the last quarter. EP Wealth Advisors LLC bought a new position in shares of PROCEPT BioRobotics in the fourth quarter valued at approximately $300,000. Finally, Mackenzie Financial Corp boosted its holdings in shares of PROCEPT BioRobotics by 8.2% in the 4th quarter. Mackenzie Financial Corp now owns 1,573,405 shares of the company’s stock worth $49,512,000 after acquiring an additional 118,971 shares in the last quarter. Institutional investors own 89.46% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on PRCT shares. Jefferies Financial Group reaffirmed a “hold” rating and set a $20.00 price objective on shares of PROCEPT BioRobotics in a research report on Wednesday. William Blair cut PROCEPT BioRobotics from an “outperform” rating to a “market perform” rating in a report on Wednesday. Weiss Ratings reiterated a “sell (e+)” rating on shares of PROCEPT BioRobotics in a research report on Friday, July 17th. Robert W. Baird set a $20.00 price objective on PROCEPT BioRobotics in a research report on Wednesday. Finally, TD Cowen reaffirmed a “buy” rating on shares of PROCEPT BioRobotics in a research report on Wednesday. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, ten have assigned a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $28.50.

About PROCEPT BioRobotics

PROCEPT BioRobotics, Inc is a medical device company specializing in the development and commercialization of robotic systems for the treatment of benign prostatic hyperplasia (BPH). The company’s technology leverages precision robotics and real-time imaging to perform minimally invasive procedures, aiming to reduce patient recovery time and improve clinical outcomes compared to traditional surgical approaches.

The company’s flagship product, the AquaBeam Robotic System, uses a high-velocity waterjet to selectively remove prostate tissue while preserving surrounding healthy structures.